Johnson & Johnson (India)

Recent papers from Johnson & Johnson (India)

1. FIN-EGFR: real-world treatment outcomes by EGFR mutational subtypes in NSCLC in Southern FinlandActa Oncologica · 2026
2. Treatment patterns, intensive treatment, and hospitalization-related burden of juvenile generalized myasthenia gravis in Japan: a retrospective cohort study using a hospital-based claims databaseFrontiers in Neurology · 2026
3. The evidentiary basis and challenges associated with studying the role of light damage on ocular health.2026
4. E152 Guselkumab and IL-17 inhibitors show comparable treatment persistence and effectiveness in psoriatic arthritis: 12-month results of the PsABIOnd observational studyLara D. Veeken · 2026
5. Abstract CT217: OrigAMI-2: A randomized, phase 3 study of amivantamab vs cetuximab, both in combination with FOLFOX or FOLFIRI, as first-line treatment in left-sided RAS/BRAF wild-type metastatic colorectal cancerCancer Research · 2026
6. Focusing on color: How the eye chooses which wavelength to see bestScience Advances · 2026
7. Clinical Evaluation of Toric Soft Lens ReproducibilityOptometry and Vision Science · 2002
8. Safety and tolerability evaluation of a novel ophthalmic viscosurgical device containing bacterial-derived hyaluronic acidCutaneous and Ocular Toxicology · 2026
9. 13P First-line subcutaneous amivantamab plus lazertinib in EGFR-mutated advanced NSCLC: Updated results from the PALOMA-2 studyESMO Open · 2026
10. Treatment continuation and factors associated with discontinuation with 3-month paliperidone palmitate in patients with schizophrenia: a post hoc analysis of post-marketing surveillance data in JapanFrontiers in Psychiatry · 2026
11. Real-World Study Assessing the Efficacy and Safety of a Novel KLEx Procedure with a Next-Generation Femtosecond Laser for Refractive Error CorrectionClinical ophthalmology · 2026
12. The socioeconomic impact of inherited retinal dystrophies (IRDs) in Belgium: A cost-of-illness studyPLoS ONE · 2026
13. X-Linked Retinitis Pigmentosa (XLRP): An Investigation of the Impact of XLRP on Health-Related Quality of Life of Carers in Great BritainAdvances in Therapy · 2026
14. Evaluating Safety Rules in Ongoing Dose‐Escalation Trials Using BOIN : A Comparative Analysis of Criteria and Their Impact on Dose‐Level Safety AssessmentsPharmaceutical Statistics · 2026
15. Visual performance measured under simulated atmospheric blue haze conditions is improved through the addition of a HEV-filtering additive to soft contact lensesVision Research · 2026
16. Menaquinone depletion resensitises bedaquiline-resistant tuberculosis2026
17. P0735Safety and Efficacy of Ustekinumab in Indian Patients with Moderate to Severe Crohn’s Disease: A Multicentre, Interventional, Phase IV studyJournal of Crohn s and Colitis · 2026
18. P0805Predictors of Endoscopic Remission at 1 Year in Patients with Ulcerative Colitis Treated with Guselkumab: Post-hoc Analyses of the QUASAR TrialJournal of Crohn s and Colitis · 2026
19. P1069Safety of guselkumab in patients aged ≥60 years with immune-mediated inflammatory diseases: a pooled analysis of registrational trials in UC, CD, PsA and PsOJournal of Crohn s and Colitis · 2026
20. P1102Impact of Disease Duration on Clinical and Endoscopic Responses at 1 Year in Patients with Crohn’s Disease Treated with Guselkumab: Pooled Analysis of the GALAXI 2 & 3 StudiesJournal of Crohn s and Colitis · 2026